Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022

Diabetes Care (2021) Vol. 45, Iss. Supplement_1, pp. S125-S143
Closed Access | Times Cited: 337

Showing 26-50 of 337 citing articles:

Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial
João Sérgio Neves, Francisco Vasques‐Nóvoa, Marta Borges‐Canha, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 189-197
Open Access | Times Cited: 39
Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies
Deqiang Zheng, Ning Li, Rui Hou, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 37
Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: an observational multicentre study
Ana Sánchez‐Fructuoso, Andrea Bedia Raba, Eduardo Banegas Deras, et al.
Clinical Kidney Journal (2023) Vol. 16, Iss. 6, pp. 1022-1034
Open Access | Times Cited: 36
Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease
Jing Luo, Robert Feldman, Katherine Callaway Kim, et al.
JAMA Network Open (2023) Vol. 6, Iss. 6, pp. e2317886-e2317886
Open Access | Times Cited: 34
Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program
Ildiko Lingvay, Ofri Mosenzon, Katelyn Brown, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 30
Cardiovascular and Renal Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Systematic Review, Meta-analysis, and Meta-regression
José M. Rodriguez‐Valadez, Malak Tahsin, Kirsten E. Fleischmann, et al.
Diabetes Care (2023) Vol. 46, Iss. 6, pp. 1300-1310
Open Access | Times Cited: 26
New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials
Tanawan Kongmalai, Varalak Srinonprasert, Thunyarat Anothaisintawee, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 26
Type 2 Diabetes and Alzheimer’s Disease: The Emerging Role of Cellular Lipotoxicity
Nicola Marrano, Giuseppina Biondi, Anna Borrelli, et al.
Biomolecules (2023) Vol. 13, Iss. 1, pp. 183-183
Open Access | Times Cited: 25
Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study
Alfredo Caturano, Raffaele Galiero, Giuseppe Loffredo, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 322-322
Open Access | Times Cited: 25
Pharmacological Support for the Treatment of Obesity—Present and Future
Marcin Kosmalski, Kacper Deska, Bartłomiej Bąk, et al.
Healthcare (2023) Vol. 11, Iss. 3, pp. 433-433
Open Access | Times Cited: 24
Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
Jimmy Gonzalez, Benjamin Bates, Soko Setoguchi, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 24
Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes
Utibe R. Essien, Balvindar Singh, Gretchen Swabe, et al.
JAMA Network Open (2023) Vol. 6, Iss. 6, pp. e2316290-e2316290
Open Access | Times Cited: 24
Pharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer’s Disease
Muna A. Adem, Boris Decourt, Marwan N. Sabbagh
Biomedicines (2024) Vol. 12, Iss. 1, pp. 99-99
Open Access | Times Cited: 15
Pathophysiology and Advances in the Therapy of Cardiomyopathy in Patients with Diabetes Mellitus
Patryk Graczyk, Aleksandra Dach, Kamil Dyrka, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 5027-5027
Open Access | Times Cited: 11
Safety and Efficacy of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus with Advanced and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis
Pajaree Krisanapan, Kanokporn Sanpawithayakul, Pattharawin Pattharanitima, et al.
Diseases (2024) Vol. 12, Iss. 1, pp. 14-14
Open Access | Times Cited: 10
SGLT2 Inhibitors in Kidney Diseases—A Narrative Review
Agata Gajewska, Jakub Wasiak, Natalia Sapeda, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4959-4959
Open Access | Times Cited: 9
Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes
Patrizia Natale, Suetonia C. Green, David J. Tunnicliffe, et al.
Cochrane library (2025) Vol. 2025, Iss. 2
Closed Access | Times Cited: 1
Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus
Jin Yu, Seung‐Hwan Lee, Mee Kyoung Kim
Endocrinology and Metabolism (2022) Vol. 37, Iss. 1, pp. 26-37
Open Access | Times Cited: 38
Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study
Sara Volpe, Giuseppe Lisco, Davide Racaniello, et al.
Nutrients (2022) Vol. 14, Iss. 12, pp. 2414-2414
Open Access | Times Cited: 36
Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs Glucagonlike Peptide-1 Receptor Agonists and Incidence of Dry Eye Disease in Patients With Type 2 Diabetes in Taiwan
Yu‐Chen Su, Jia‐Horung Hung, Kai‐Cheng Chang, et al.
JAMA Network Open (2022) Vol. 5, Iss. 9, pp. e2232584-e2232584
Open Access | Times Cited: 35
A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes
Ryotaro Bouchi, Tatsuya Kondo, Yasuharu Ohta, et al.
Journal of Diabetes Investigation (2022) Vol. 14, Iss. 1, pp. 151-164
Open Access | Times Cited: 33
Defining preventive cardiology: A clinical practice statement from the American Society for Preventive Cardiology
Charles German, Seth J. Baum, Keith C. Ferdinand, et al.
American Journal of Preventive Cardiology (2022) Vol. 12, pp. 100432-100432
Open Access | Times Cited: 32
How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma
Konstantinos Arvanitakis, Theocharis Koufakis, Kalliopi Kotsa, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4651-4651
Open Access | Times Cited: 30
Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
Marta Baviera, Andreana Foresta, Pierluca Colacioppo, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 29
Repurposing antidiabetic drugs for rheumatoid arthritis: results from a two-sample Mendelian randomization study
Chenxi Qin, Lina‐Marcela Diaz‐Gallo, Bowen Tang, et al.
European Journal of Epidemiology (2023) Vol. 38, Iss. 7, pp. 809-819
Open Access | Times Cited: 20

Scroll to top